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The relevance of circadian rhythms in irinotecan and oxaliplatin tolerability was investigated with regard to antitumour activity.
Mice bearing Glasgow osteosarcoma (GOS) received single agent irinotecan (50 or 60 mg kg
71 per day) or oxaliplatin (4 or
5.25 mg kg
71 per day) at one of six dosing times expressed in hours after light onset (3, 7, 11, 15, 19 or 23 hours after light
onset). Irinotecan (50 mg kg
71 per day) and oxaliplatin (4 or 5.25 mg kg
71 per day) were given 1 min apart at 7 or 15 hours
after light onset, or at their respective times of best tolerability (7 hours after light onset for irinotecan and 15 hours after light
onset for oxaliplatin) or worst tolerability (15 hours after light onset for irinotecan and 7 hours after light onset for oxaliplatin).
Tumour growth rate was nearly halved and per cent increase in estimated life span (% ILS) was – doubled in the mice
receiving irinotecan at 7 hours after light onset as compared to 15 hours after light onset (P50.05). Results of similar
magnitude were obtained with oxaliplatin for both endpoints, yet with 7 hours after light onset corresponding to least efﬁcacy
and 15 hours after light onset to best efﬁcacy (P50.05). Irinotecan addition to oxaliplatin proved therapeutic beneﬁt only if
the schedule consisted of irinotecan administration at 7 hours after light onset and oxaliplatin delivery at 15 hours after light
onset, i.e. when both drugs were given near their respective ‘best’ circadian times. These would correspond to the middle of
the night for irinotecan and the middle of the day for oxaliplatin in humans.
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Irinotecan and oxaliplatin are two recently available drugs which
have largely improved the efﬁcacy of chemotherapy against
metastatic colorectal cancer (Cunningham et al, 1998; Rougier
et al, 1998; De Gramont et al, 2000; Douillart et al, 2000; Giac-
chetti et al, 2000). Gastrointestinal and haematologic toxicities
are dose limiting for both agents, while irinotecan can also
cause asthenia and oxaliplatin can produce peripheral sensory
neuropathy.
Experiments in mice have indicated that the tolerability and the
efﬁcacy of both agents varied signiﬁcantly as a function of drug
dosing time, as a result of the rhythms which modulate cell meta-
bolism and proliferation along the 24 h time scale (Le ￿vi, 1997).
Cellular circadian rhythms are generated by interacting molecular
loops, involving at least eight speciﬁc genes (Balsalobre et al,
1998; Dunlap, 1999; Van der Horst et al, 1999; Whitmore and
Sassone-Corsi, 1999). They are coordinated by the suprachiasmatic
nuclei, a group of neurons located at the ﬂoor of the hypothalamus
(Klein et al, 1991). The regular alternation of light and darkness
over 24 h synchronises mammalian circadian rhythms and consti-
tute a reference for predicting the times of peak and trough of
cellular metabolism and proliferation.
As a consequence of this circadian time structure, the haemato-
logic and intestinal toxicities of oxaliplatin were signiﬁcantly
reduced by the administration of this drug near the middle of
darkness as compared to midlight in mice (Boughattas et al,
1989; Li et al, 1998). The clinical relevance of this ﬁnding was
subsequently demonstrated in randomised trials involving cancer
patients treated with oxaliplatin as a single agent or combined with
5-ﬂuorouracil and leucovorin (Caussanel et al, 1990; Le ￿vi et al,
1997, 2000). Indeed, the chronomodulated administration of oxali-
platin, with peak delivery at 16:00 h resulted in fewer patients
presenting with neutropenia, diarrhoea or peripheral sensory
neuropathy as compared to constant rate infusion or chronomodu-
lated administrations with peak delivery rates occurring 9 or 12 h
apart.
Three studies have also indicated that the tolerability of camp-
tothecin derivatives – irinotecan and 9-aminocamptothecin –
varied as a function of time of administration in mice (Filipski
et al, 1997; Ohdo et al, 1997; Kirichenko and Rich, 1999). Body
weight loss as well as intestinal and haematological toxicities were
least following treatment delivery in the second half of the rest
span of mice. A pilot clinical study has suggested that a chronomo-
dulated infusion of irinotecan could improve the tolerability of this
drug, an issue which is currently being investigated in a rando-
mized trial (Giacchetti et al, 1997).
We have studied the relationship between the circadian rhythm
in the tolerability of irinotecan and that of oxaliplatin and the
anticancer efﬁcacy of these drugs in mice. We also have examined
the activity of their combination along the circadian time scale,
since several reports have suggested synergistic activity
(Scheithauer et al, 1999; Wasserman et al, 1999; Goldwasser et
al, 2000).
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Study design
Four experiments were conducted in a total number of 400 male
B6D2F1 mice bearing Glasgow Osteosarcoma (GOS) at a palpable
stage. For this reason, all treatments were applied 5 days after
tumour transplantation. Injections were repeated daily for 4 conse-
cutive days (d5–8) (Table 1).
The role of dosing time upon single agent irinotecan or oxalipla-
tin activity was investigated in experiments 1 and 2 respectively. All
the mice were synchronised with an alternation of 12 h of light (L)
and 12 h of darkness (D) (LD 12:12). Injection times were
expressed in hours after light onset (HALO). Each drug was given
daily at either dose level at one of six dosing times, staggered by
4 h. Controls received NaCl 0.9% (experiment 1) or 5% glucose
(experiment 2) at each dosing time. Experiments 3 and 4 tested
the role of dosing time of irinotecan – oxaliplatin combination.
In experiment 3, single agent irinotecan was given at 7 or 15
HALO. Combined irinotecan and oxaliplatin were injected 1 min
apart at either dosing time, selected on the basis of the results from
experiments 1 and 2. In experiment 4, both drugs were given at 15
HALO (1 min apart), or irinotecan was given at 7 HALO and
oxaliplatin at 15 HALO, near their respective ‘best times’ as single
agents, or irinotecan was administered at 15 HALO and oxaliplatin
at 7 HALO, near their respective ‘worst time’ as single agents.
Drugs
Irinotecan (solution for intravenous (i.v.) injection, 20 mg ml
71)
was kindly provided by Aventis Pharma (Montrouge, France).
The drug was diluted in 0.9% sodium chloride on each study
day, prior to injections. Oxaliplatin (solution for i.v. injection,
5m gm l
71) was kindly provided by Sanoﬁ-Synthe ￿labo (Montpel-
lier, France). The drug was diluted in 5% glucose on each study
day prior to injections. The ﬁnal drug solutions were injected i.v.
into the right retro-orbital venous sinus (10 ml kg
71 of body
weight). Mice received an average of 0.28 ml of solution at each
injection. Irinotecan and oxaliplatin doses were selected on the
basis of preliminary experiments in this model at our laboratory
(D’Attino et al, unpublished results). For experiment 1, single
agent irinotecan dose was 50 mg kg
71 per day (total dose of
200 mg kg
71)o r6 0 m g k g
71 per day (total of 240 mg kg
71),
which represents a 20% dose escalation. For experiment 2, single
agent oxaliplatin dose was 4 mg kg
71 per day (total dose of
16 mg kg
71) or 5.25 mg kg
71 per day (total dose of 21 mg kg
71),
which represents a 31% dose escalation. For experiments 3 and 4,
the doses were 50 mg kg
71 per day for irinotecan and 4 or
5.25 mg kg
71 per day for oxaliplatin.
Animals and synchronisation
All experiments were carried out in accordance with the guidelines
approved by the UKCCCR.
Male B6D2F1 mice, 6 to 7 weeks of age, were purchased from
IFFA-Credo (L’Arbesle, France). They were housed two per cage
with water and food ad libitum, and allocated to one of the several
treatment groups planned for each experiment. Cages from each
group were placed on a different shelf of an autonomous chrono-
biological animal facility (ESI-Flufrance, Arcueil, France). Each
facility has six soundproof, temperature-controlled compartments,
each having its own programmable lighting regimen, correspond-
ing to six different circadian stages each one located 4 h apart.
Each compartment was constantly provided with ﬁltered air deliv-
ered at an adjusted rate.
Six circadian times were tested during the light span, when the
animals are usually at rest (3, 7 or 11 HALO) or during darkness,
when the animals are usually active (15, 19 or 23 HALO).
Rectal temperature was measured with a rectal probe after a
minimum of 2 weeks’ synchronisation in groups of mice from each
compartment.
Tumour
Glasgow osteosarcoma (GOS), a tumour known to display inter-
mediate sensitivity to both irinotecan and oxaliplatin was
provided by the Research Centre of Aventis Pharma (Vitry sur
Seine, France). The tumour was maintained in C57BL/6 female
mice over 6 weeks of age and passaged every 2 weeks as bilateral
subcutaneous (s.c.) implants in donor female C57BL/6 mice until
the lower tumour weight reached 700 mg.
Donor mice were sacriﬁced, their tumours were removed, placed
into Hank’s balanced salt solution and dissected into fragments
measuring 363 mm using a grill scaled to these values. Recipient
experimental mice were transplanted with one tumour fragment in
each ﬂank, using a trocar.
Mice with tumour weight reaching 2000 mg along the course of
the study were sacriﬁced for ethical reasons and were considered as
dead from tumour progression on this date.
Study endpoints
Body weight was measured with a precision balance and tumour
weight was determined using a caliper, three times a week:
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Table 1 Summary of experimental designs
Total N of mice
Daily dose (mg kg
71 per
day)
Circadian time of
Experiment treated/control Schedule Irinotecan Oxaliplatin injection (HALO)
1 107/36 d 5–8 50 –
60 – 3, 7, 11, 15, 19 or 23
2 109/36 d 5–8 – 4
– 5.25 3, 7, 11, 15, 19 or 23
3 36/9 d 5–8 50 – 7 or 15
50 4 7?15 or 15?15
4 58/9 d 5–8 50 4
50 5.25 7?15, 15?15 or 15?7
Characteristics of the experiments on the chronoefﬁcacy of single agent irinotecan (experiments 1 and 3), or oxaliplatin
(experiment 2), and combined irinotecan and oxaliplatin (experiments 3 and 4). Each group of B6D2F1 mice inoculated
wth Glasgow osteosarcoma on day 0 received daily treatment on days 5 to 8. Time of injection was expressed in hours after
light onset (HALO), with mice synchronised with alternation of 12 h of light and 12 h of dark. The time of injection of irinotecan
and that of oxaliplatin in the combinations are indicated by their respective HALO, separated by an arrow (irinote-
can?oxaliplatin). A control group of non-treated tumour-bearing mice was included in each experiment.
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Mortality was recorded daily for up to 60 days.
Time to reach a mean tumour weight of 2 g was considered as
an estimate of survival. The median day to reach this endpoint was
used as median survival time estimate (MSTE) in order to compute
the percentage of Increase in Life Span (%ILS) as described else-
where (Tampellini et al, 1998).
Statistical analysis
Rectal temperature, tumour weight and body weight changes were
analysed with analysis of variance (ANOVA). Differences in
tumour weight were analysed in data truncated on the study day
preceding the death of 50% of the mice in one treatment group.
Survival curves were drawn according to Kaplan–Meier, and
differences in survival were tested using the log-rank method.
Proportions of mice with tumour 42 g were compared using
the w
2 test. All standard statistics were performed using SPSS for
Windows software. The statistical signiﬁcance of circadian rhyth-
micity was further documented by cosinor analysis (Nelson et al,
1979).
RESULTS
Synchronisation of mice
Mean rectal temperature of tumour bearing mice (+s.e.m.) varied
from 35.1+0.18C in the light span up to 38.6+0.18C in the dark
span. ANOVA validated signiﬁcant differences as a function of
sampling time (P50.001). Cosinor analysis revealed a signiﬁcant
circadian rhythm for each experiment (P50.01). The acrophase
(time of maximum in ﬁtted curve) was localised at 18.28 HALO
(95% C.L.,+68 min), close to the middle of the dark span.
Tumour growth and survival of control mice
All the control mice died from tumour progression between 11
days and 19 days after tumour inoculation. No signiﬁcant differ-
ence in tumour growth or survival was found as a function of
the circadian time of tumour inoculation, whether the data were
examined separately for each experiment or pooled. Overall, the
MSTE of control mice ranged from 13 days (experiment 3) to 15
days (experiment 4) without any statistically signiﬁcant difference
between the four experiments.
Single agent irinotecan (experiment 1)
Lethal toxicity A single mouse receiving 50 mg kg
71 per day of
irinotecan died from toxicity immediately after the fourth dose, at
15 HALO. Early mortality was encountered within the ﬁrst two
treatment days in the mice receiving 60 mg kg
71 per day. No
death was found following drug dosing at 7 HALO. Conversely,
mortality rate was 30% in the mice treated at 19 HALO and
55.5% in those injected at 23 HALO (w
2=9.7; d.f.=5; P=0.08).
Body weight change Mean body weight reached a nadir on the
fourth treatment day, without any dose effect (F from
ANOVA=0.7, N.S.). Conversely, dosing time signiﬁcantly inﬂu-
enced body weight loss at each dose level (two-way ANOVA,
Fdose=0.6, NS; Ftime=11.2, P50.0001). Body weight loss at nadir
was nil in the mice treated at 7 or 11 HALO, whatever the dose
level, and largest in those treated at 19 HALO (7.5+2.1% with
50 mg kg
71 per day and 14.6+2.8% with 60 mg kg
71 per day).
Tumour growth Irinotecan produced no partial or complete
tumour regression, but rather slowed down tumour growth as
compared to controls. Tumour size was compared as a function
of dose and dosing time before mortality from tumour progres-
sion. Tumour growth was slower in the mice treated at 7
HALO as compared to those injected at 23 HALO (Table 2).
Death from tumour progression occurred in the mice receiving
50 mg kg
71 per day between the 14th and the 26th day after
tumour inoculation (Figure 1A). At this dose level, MSTE was
19 days at 7 HALO and 16 days for all the other treatment times,
with corresponding %ILS of 58.3 and 21.4%. Death from tumour
progression occurred in the mice receiving 60 mg kg
71 per day
between the 17th and the 26th day after tumour inoculation.
The survival curves differed signiﬁcantly as a function of treat-
ment time for the higher dose and for the pooled data at both
dose levels (P from log rank 50.05). At the higher dose level,
MSTE ranged from 6 days at 23 HALO (%ILS, 750%) to 21
days at 7 HALO (%ILS, +75%).
Single agent oxaliplatin (experiment 2)
Lethal toxicity No mouse died from toxicity following the
administration of 4 mg kg
71 per day. Conversely, 12.7% of toxic
deaths were encountered in the mice treated with 5.25 mg kg
71
per day. In this latter group, the mortality rate was 22.2% in the
mice injected at 3 HALO, as compared to 12.5% in those treated
at 15 HALO and 11.1% in the animals receiving the drug at 19
HALO (w
2=0.9; NS).
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Table 2 Tumour size in mice receiving irinotecan, oxaliplatin or their combination as a function of dose and time of
administration
Dose
Circadian time of injection (HALO)
Exp. Agent mg kg
71 per day Day
a 3 7 11 15 19 23
1 Irinotecan 50 16 1764+258 997+283 1459+660 1458+788 1561+474 2053+602
60 17 1593+316 1258+245 1073+272 1372+258 1469+256 1976+538
2 Oxaliplatin 4 23 1778+270 1844+232 1472+225 1110+163 1774+262 1291+244
5.25 26 1965+446 1657+259 2151+345 968+435 1522+398 2035+402
7 15 7–7 7–15 15–15 15–7
3 Irinotecan 50 17 685+197 1277+209
Irin+Oxal 50+4 26 1415+194 1264+249
4 Irin+Oxal 50+4 25 1152+188 1242+196 1927+160
Irin+Oxal 50+5.25 25 892+121 664+161 1889+178
aStudy day preceding the death of 50% of the mice in one time point group. Maximum and minimum values are underlined and boxed,
respectively. HALO=hours after light onset.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(6), 999–1005Body weight change Mean body weight loss reached a nadir 5 or
12 days after treatment onset in the mice treated with 4 or
5.25 mg kg
71 per day of oxaliplatin respectively. The average
maximum weight loss was 5.9+0.7% in the mice receiving
4m gk g
71 per day as compared to 9.2+1.0% in those treated with
5.25 mg kg
71 per day. Body weight loss at nadir differed signiﬁ-
cantly as a function of both dose (F from ANOVA=16.6,
P50.0001) and dosing time at each dose level (F from ANOVA=6,
P50.0001). Maximum weight loss following the administration of
5.25 mg kg
71 per day was largest in the mice treated during the
light span (12.6+2.5% at 3 HALO, 10.0+2.2% at 7 HALO) as
compared to those given the drug during the dark span
(4.3+2.1% at 15 HALO and 5.4+1.3% at 19 HALO).
Tumour growth Tumour growth was slower in the mice receiv-
ing oxaliplatin at 15 HALO as compared to those treated at 7 or 11
HALO (Table 2). All the mice which received 4 mg kg
71 per day
of oxaliplatin were sacriﬁced for tumour reaching 2 g between 19
and 35 days after tumour inoculation. The mice receiving
5.25 mg kg
71 per day were killed for this reason between 19 and
47 days after tumour inoculation, except one cured animal. MSTE
ranged from 23 to 33 days as a function of dose (P from Log
Rank=0.04). Survival curves also differed signiﬁcantly as a function
of dosing time (Figure 2). Thus, at the lower dose level, MSTE was
30 days in the mice treated at 15 HALO (%ILS, 114%) as
compared to 23 days in those injected at 3 HALO (%ILS, 64%)
(Figure 2A). At the higher dose level, MSTE was 33 days following
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Figure 1 Percentage of GOS-bearing B6D2F1 male mice with tumours less than 2 g. Animals received four consecutive daily i.v. injections of irinotecan at
one of six dosing times, expressed in hours after light onset (HALO). Two dose levels were tested: 50 mg kg
71 per day (A)o r6 0m gk g
71 per day (B).
Differences in curves of estimated survival (time to reach tumour weight of 2 g) as a function of dosing time were tested by log rank (P=0.19, A and
P50.05 B).
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Figure 2 Percentage of GOS-bearing B6D2F1 male mice with tumours less than 2 g. Animals received four consecutive daily i.v. injections of oxaliplatin at
one of six dosing times, expressed in hours after light onset (HALO). Two dose levels were tested: 4 mg kg
71 per day (A) or 5.25 mg kg
71 per day (B).
Curves of estimated survival (time to reach tumour weight of 2 g) differed as a function of dosing time for each dose level (P from log rank 50.001, A and
P=0.018, B).
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British Journal of Cancer (2002) 86(6), 999–1005 ã 2002 Cancer Research UKdosing at 15 HALO (%ILS, 136%) and 26 days in the mice given
the drug at 3 HALO (%ILS, 86%). The single cured mouse had
received 5.25 mg kg
71 per day at 15 HALO and it was still alive
on day 90 (Figure 2B).
Irinotecan-oxaliplatin combination (experiments 3 and 4)
Lethal toxicity No mortality was found in experiment 3. In
experiment 4, lethal toxicity was limited to the combination invol-
ving 5.25 mg kg
71 per day of oxaliplatin and varied as a function
of treatment time and schedule. Mortality rate ranged from 33.3%
in the mice given both drugs at 15 HALO as compared to 9.1% in
those receiving irinotecan at 15 HALO then oxaliplatin at 7 HALO
and 8.3% of the mice treated with irinotecan at 7 HALO then
oxaliplatin at 15 HALO (w
2=0.9; N.S.).
Body weight change In experiment 3, mean body weight loss
reached a nadir 10 days after tumour inoculation. The average
maximum weight loss (+s.e.m.) was 15+0.9% with both drugs
given at 7 HALO and 10+1.8% if they had been given at 15
HALO (F from ANOVA=22.7, P50.001). In experiment 4, mean
body weight loss reached a nadir 11 days after tumour inoculation.
The average maximum weight loss was 16+3.4% in the mice
injected at 15 HALO with irinotecan and the higher oxaliplatin
dose, as compared to 10+0.9% in the animals given irinotecan
at 7 HALO and the lower oxaliplatin dose at 15 HALO.
Tumour growth In experiment 3, the combination delayed by 9
days the time to reach 2 g in 50% of the mice from one treatment
group as compared to irinotecan alone (Table 2). Tumour growth
inhibition with single agent irinotecan was nearly twice as large at 7
HALO as compared to 15 HALO. The irinotecan–oxaliplatin
combination seemed to be more active when both drugs were given
at 15 HALO rather than at 7 HALO (Table 2).
The administration of oxaliplatin 1 min after that of irinotecan
improved estimated survival as compared to single agent irinote-
can, whether both agents were given at 7 HALO (%ILS, 115%
for the combination vs 62% for single agent irinotecan) or at 15
HALO (%ILS, 154% for the combination vs 46.1% for single agent
irinotecan).
Tumour growth retardation varied signiﬁcantly as a function of
combination dosing time (P from log rank 50.005) (Figure 3).
Thus, the delivery of both drugs 1 min apart resulted in longer
MSTE and %ILS in the mice treated at 15 HALO as compared
to those injected at 7 HALO (MSTE, 33 vs 28 days; %ILS, 154%
vs 115%).
In experiment 4, maximum tumour reduction was achieved with
the highest dose of oxaliplatin (5.25 mg kg
71 per day) combined
with irinotecan. Oxaliplatin was more effective at 15 HALO, irre-
spective of dose (Table 2). The administration of irinotecan at 15
HALO and that of oxaliplatin at 7 HALO was clearly less effective
than any other combination schedule.
Irinotecan–oxaliplatin combination proved of no beneﬁt as
compared to single agent oxaliplatin, if irinotecan was given at
15 HALO and oxaliplatin at 7 HALO (MSTE, 25 days; %ILS,
77%). The most effective regimen consisted in the administration
of irinotecan at 7 HALO and oxaliplatin at 15 HALO (Figure 4).
The MSTE of the mice receiving this latter schedule was 39 days
if the oxaliplatin dose was 4 mg kg
71 per day (%ILS, 160%) and
41 days after an oxaliplatin dose of 5.25 mg kg
71 per day
(%ILS, 173%). Statistically signiﬁcant differences were found as a
function of irinotecan–oxaliplatin circadian schedule (P from log
rank 50.005).
DISCUSSION
The antitumour efﬁcacy of irinotecan and oxaliplatin, both as
single agents and combined, varied signiﬁcantly as a function of
circadian dosing time in tumour-bearing mice.
Glasgow osteosarcoma was chosen since it displayed intermedi-
ate sensitivity to both drugs, a property which is also shared by
human colorectal cancer and which is useful for studying the bene-
ﬁt from irinotecan–oxaliplatin combination.
The tolerability of irinotecan, as assessed with body weight
change and survival, was best in the second half of the rest span
in GOS-bearing mice, a result similar to that previously reported
in non-tumour bearing animals (Filipski et al, 1997; Ohdo et al,
1997). Pseudocholinergic shock was responsible for immediate
mortality in the mice receiving 60 mg kg
71 per day. This toxic
effect was encountered in 30% of the mice treated at 19 HALO,
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Figure 3 Percentage of GOS-bearing B6D2F1 male mice with tumours
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71 per day) or irinotecan-oxaliplatin combination (50 and
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animals treated at 7 HALO. As a result, the toxicity rhythm largely
contributed to the signiﬁcant dosing time-related differences in
survival. On the other hand, tumour growth inhibition with the
non toxic dose (50 mg kg
71 per day) was nearly twice as large
in the mice treated at 7 HALO also, as compared to those receiving
the drug during the dark span, both in experiments 1 and 3. As a
result, the %ILS was nearly twice as large in the mice receiving a
toxic or a non-toxic dose at 7 HALO as compared to 19 HALO.
This suggests that GOS susceptibility to irinotecan displays a circa-
dian pattern. Thus, the full dose-efﬁcacy relationship could be
explored meaningfully only at 7 HALO, an issue which was beyond
the scope of the current study.
In the second part of the study a strong rhythm in oxaliplatin
efﬁcacy was found at either dose level. No toxic death was
produced by 4 mg kg
71 per day of oxaliplatin. For the higher dose
(5.25 mg kg
71 per day) lethal toxicity was 12.7%. Both lethal toxi-
city and body weight loss were nearly twice as high in the mice
treated at early to mid light as compared to near mid dark. The
tolerability rhythm was similar to that reported with a single dose
of this drug (Li et al, 1998; Boughattas et al, 1989). In the present
study, tumour growth inhibition and %ILS were also largest at 15
HALO and poorest at 3 or 7 HALO. Thus, the rhythm in oxalipla-
tin efﬁcacy overlapped that in tolerability, with best therapeutic
index with drug dosing at 15 HALO.
We subsequently explored the role of dose interval and circadian
time for irinotecan–oxaliplatin combination. In order to avoid
irinotecan early mortality, this agent was only given at a dose of
50 mg kg
71 per day. Irinotecan was combined with either oxalipla-
tin dose (4 or 5.25 mg kg
71 per day64 days). In experiment 3,
the administration of both drugs 1 min apart signiﬁcantly slowed
tumour growth and prolonged %ILS as compared to single agent
irinotecan. The most effective schedule consisted in the delivery
of both drugs at 15 HALO. In experiment 4, this latter schedule
was compared to the administration of both drugs near their
respective ‘best’ times (7 HALO for irinotecan and 15 HALO for
oxaliplatin) or ‘worst’ times (15 and 7 HALO). This latter schedule
was clearly less active with regard to tumour growth inhibition
than both other treatment regimens, indicating the need to admin-
ister oxaliplatin at 15 HALO. Nevertheless, nearly 30% of the mice
receiving both drugs at 15 HALO died from lethal toxicity as
compared to less than 10% with the other schedules. This supports
the administration of irinotecan at 7 HALO and oxaliplatin at 15
HALO as the best tolerated and the most active combination
schedule.
We compared the increase in survival estimate (%ILS) from the
irinotecan–oxaliplatin combination schedules with that from each
single agent (Figure 5). The combination was signiﬁcantly more
effective than any single drug only if irinotecan was given in the
middle of the rest span (7 HALO) and oxaliplatin near the middle
of the activity span (15 HALO).
The results support that a synergistic activity of these drugs
requires their administration near their respective ‘best’ circadian
times. They are in line with the coincidence between the time of
best efﬁcacy and that of best tolerability which was recently shown
for single agent doxorubicin, docetaxel or vinorelbine and for
docetaxel–doxorubicin combination (Tampellini et al, 1998;
Filipski et al, 1999; Granda et al, 2001).
The results from the present study support the chronomodu-
lated infusion of irinotecan and oxaliplatin in patients with
metastatic colorectal cancer with respective peak delivery rate near
5:00 and 16:00 h respectively, in order to optimize both tolerability
and efﬁcacy of this treatment schedule.
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